Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03408860 · ClinicalTrials.gov registry record · NA
Isolating Mechanisms in the Treatment of Borderline Personality Disorder
A NA study, sponsored by Boston University Charles River Campus.
- Completed
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT03408860 is a NA study that has completed, run by Boston University Charles River Campus. The registered enrollment target is 8 participants.
The verdict
NCT03408860, a NA study, has completed, sponsored by Boston University Charles River Campus.
- COMPLETED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
Borderline personality disorder (BPD) is a commonly occurring, severe, and costly condition that interferes greatly with quality of life. Considerable comorbidity with other disorders and existing multicomponent treatments with largely untested putative mechanisms of action represent obstacles for effective dissemination of BPD treatment; in light of this gap, the purpose of the present study is to isolate the effects of individual treatment components on putative mechanisms implicated in both BPD. This study will answer important theoretical questions about the mechanism of treatment change, and might lead to more efficacious, cost-effective, and easily disseminable treatment strategies for BPD, a severe and understudied disorder.
Interventions
- OTHER Countering Emotional Behaviors Module from Unified Protocol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2017-10-15 |
| Est. Completion | 2020-08-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03408860
The ClinicalTrials.gov registry entry for NCT03408860 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston University Charles River Campus, which has 104 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Countering Emotional Behaviors Module from Unified Protocol is the first listed.
NCT03408860 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03408860 about?
NCT03408860 is a clinical study titled "Isolating Mechanisms in the Treatment of Borderline Personality Disorder". Borderline personality disorder (BPD) is a commonly occurring, severe, and costly condition that interferes greatly with quality of life. Considerable comorbidity with other disorders and existing multicomponent treatments with largely untested putative mechanisms of action represent obstacles for e...
What is the current status of trial NCT03408860?
This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2017-10-15. Estimated completion is 2020-08-30.
What interventions are being tested in trial NCT03408860?
The interventions under investigation include: Countering Emotional Behaviors Module from Unified Protocol (OTHER).
Who is sponsoring clinical trial NCT03408860?
This trial is sponsored by Boston University Charles River Campus, which has 104 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.